Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
Meuth SG, Wolff S, Mück A, Willison A, Kleinschnitz K, Räuber S, Pawlitzki M, Konen FF, Skripuletz T, Grothe M, Ruck T, Huttner HB, Kleinschnitz C, Bopp T, Pul R, Cree BAC, Hartung HP, Möllenhoff K, Pfeuffer S.
Meuth SG, et al. Among authors: mollenhoff k.
Ann Neurol. 2024 Nov 25. doi: 10.1002/ana.27143. Online ahead of print.
Ann Neurol. 2024.
PMID: 39582359